Mylan in India

Mylan is one of the world’s leading global pharmaceutical companies, with a significant and growing presence in India. We have a workforce of approximately 35,000 people, about half of which are based in India. Our broad portfolio includes generic and brand name products in a variety of dosage forms, which are sold in more than 165 countries and territories.

Mylan’s business in India began in 2007 with the acquisition of Matrix Laboratories Limited. The deal transformed Mylan overnight into one the world’s largest manufacturers of active pharmaceutical ingredients (API) and allowed us to vertically integrate the production of our finished dosage form (FDF) medicines.

Today, Mylan has 47 manufacturing facilities, 19 of which are located in India. Those 19 facilities include eight API facilities, six OSD facilities and five Injectables facilities, which manufacture our high quality medicines for markets all over the world. Our manufacturing capabilities in India include a range of dosage forms, such as tablets, capsules and injectables, in a wide variety of therapeutic categories.

Our API businesses provides hiqh-quality APIs to third parties around the world and antiretroviral products for people living with HIV/AIDS. More than 40% of the nearly 21 million HIV+ patients being treated today – and 60% of the world’s HIV+ children – depend on one of our products.

In addition, Mylan has a growing commercial presence  domestically. Our current franchises include Critical Care, Hepato Care, HIV Care, Onco Care and Women’s Health Care.

Our presence in India goes beyond manufacturing, sales and marketing. Hyderabad is home to one of Mylan’s two global R&D centers of excellence . The center has extensive experience working with health authorities from multiple countries. It also is fully integrated with the company’s global R&D function, creating a unique and efficient, ‘round-the-clock research, development, clinical and regulatory capability.


  • Mylan in India at a Glance

    2007: Mylan acquired Matrix Laboratories Limited
    19: Manufacturing facilities
    >250+: APIs in pipeline
    ~15,000: Workforce
    ~50%: Scientific Affairs workforce

    Fact Sheet

  • Sanjeev Sethi

    Chief Operating Officer

    Sanjeev Sethi is Mylan’s Chief Operating Officer. In his career spanning more than two decades, Mr. Sethi has held key leadership positions across critical functions such as R&D, Regulatory Affairs, Technical Services and Manufacturing.

    As Chief Operating Officer, Mr. Sethi leads all scientific functions within Mylan including R&D, Regulatory Sciences, Clinical Operations, Technical Operations, Portfolio Management, Medical and Product Safety and Risk Management (PRSM) operations. He also heads the Global Launch Management Group and oversees new product launches globally.

    Mr. Sethi joined Mylan in 2007, through the Matrix acquisition and has held a series of increasingly significant positions with the company since then. Most recently, he was the Head of the company’s Global Injectable vertical and led the operational execution for all injectable products in Mylan’s portfolio. Prior to this, he held positions of Head of Global Scientific Affairs and Head of Global Generics R&D.

    Having earned a master’s degree in Pharmaceutical Sciences from the Punjab University, Mr. Sethi also holds 40 international patents to his credit.

    Mr. Sethi also worked for Ranbaxy Laboratories and Sandoz in multiple functions, including R&D, Regulatory Affairs, Technical Services and Manufacturing Operations.
  • Rakesh Bamzai

    Rakesh Bamzai_

    President, India and Emerging Markets

    Rakesh Bamzai is President, India Commercial and Emerging Markets at Mylan Pharmaceuticals Private Limited and Managing Director and CEO of Mylan Laboratories Limited. Based in Bangalore, Mr. Bamzai has close to three decades of experience in the Indian and global biopharmaceutical industry.

    In his current role, Mr. Bamzai is responsible for leading Commercial Operations for Mylan’s branded, branded generics, generics, biosimilars, antiretroviral (ARV) and active pharmaceutical ingredient (API) businesses in India and Emerging Markets. During his tenure with Mylan, Mr. Bamzai has championed various initiatives to transform Mylan’s businesses across the highly dynamic countries within the region. He has been instrumental in establishing a robust commercial and distribution platform and forged strategic partnerships with the aim of enhancing access and affordability in line with the company’s vision. Further, Mr. Bamzai has led multiple integration efforts to consolidate and streamline businesses within Mylan’s India and Emerging Markets region.

    Mr. Bamzai also has developed an expertise in the global biopharmaceutical business throughout his career and has a track record of scaling up businesses from scratch. With a keen eye for leveraging valuable therapies and portfolios that fulfill unmet needs, he has led marketing efforts that have influenced development pipelines created successful pillar brands across therapies in various international markets.

    Mr. Bamzai studied Chemical Technology at the University Department of Chemical Technology, now known as the Institute of Chemical Technology at the University of Mumbai, where he was named a ‘Distinguished Alumni’ by the Vice Chancellor of the university.